SEC For																				
FORM 4 UNI				ED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					ENT OF CHANGES IN BENEFICIAL OWNERSHIP led pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* Bellemin Jean-Marc					<u>10</u>	2. Issuer Name and Ticker or Trading Symbol <u>IOVANCE BIOTHERAPEUTICS, INC.</u> [IOVA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				ner	
(Last)(First)(Middle)C/O IOVANCE BIOTHERAPEUTICS, INC.999 SKYWAY ROAD, SUITE 150					3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021										Chief Financial Officer					
(Street) SAN CARLOS CA 94070															 A. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City) (State) (Zip)																				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)					action	2. E ar) if	Curities Acq 2A. Deemed Execution Date, f any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)) or 4 and 5. Amou Securitie Benefici Owned F Reported Transcot		nt of 6. Ov es Form ally (D) o Following (I) (In d		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Code V Amount (A) OF (D) Price Instatutin(s) (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) Image: Code of the securities of																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Ti	4. Transaction Code (Instr.		5. Number of		6. Date Exe Expiration (Month/Day	Date	ble and 7. Title and Am of Securities			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	s Ily I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or	ount nber ıres						
Restricted Stock Units	(1)	06/14/2021			A		37,700		(2)		(2)	Commo stock	¹ 37,	,700	\$0.00	37,70	0	D		

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022.

<u>/s/ Jean-Marc Bellemin</u> <u>06/16/2021</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.